Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple supplement tame diabetes and heart risk?

NCT ID NCT07503548

First seen Apr 26, 2026 · Last updated Jun 23, 2026 · Updated 8 times

Summary

This study tests whether tributyrin, a dietary supplement that turns into butyrate in the body, can improve blood sugar control, reduce inflammation, and lower heart disease risk in people with type 2 diabetes. Sixty participants at high risk for heart problems will receive either tributyrin or a placebo alongside their usual diabetes treatment for 12 weeks. The goal is to see if this safe, natural compound can offer extra benefits beyond standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Matareya Teaching Hospital

    Cairo, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tributyrin (a dietary supplement that turns into butyrate in the body)

What this could lead to

If it works, this could point toward a simple, safe supplement to help manage blood sugar and reduce heart disease risk in people with type 2 diabetes.

What could go wrong

This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The supplement may not show significant benefits over standard care.

Conditions

The condition(s) this trial relates to.

diabetes mellitus Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.